Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies

Functional impairment and selective depletion of CD4+ T cells, the hallmark of AIDS, are at least partly caused by human immunodeficiency virus (HIV-1) type I binding to the CD4 molecule and infecting CD4+ cells. It may, therefore, be of therapeutic value to target an target an antiviral agent to CD...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 347; no. 6288; pp. 92 - 95
Main Authors Zarling, J.M, Moran, P.A, Haffar, O, Sias, J, Richman, D.D, Spina, C.A, Myers, D.E, Kuebelbeck, V, Ledbetter, J.A, Uckun, F.M
Format Journal Article
LanguageEnglish
Published London Nature Publishing 06.09.1990
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Functional impairment and selective depletion of CD4+ T cells, the hallmark of AIDS, are at least partly caused by human immunodeficiency virus (HIV-1) type I binding to the CD4 molecule and infecting CD4+ cells. It may, therefore, be of therapeutic value to target an target an antiviral agent to CD4+ cells to prevent infection and and to inhibit HIV-1 production in patients' CD4+ cells which contain proviral DNA. We report here that HIV-1 replication in normal primary, CD4+ T cells can be inhibited by pokeweed antiviral protein, a plant protein of relative molecular mass 30,000, which inhibits replication of certain plant RNA viruses, and of herpes simplex virus, poliovirus and influenza virus. Targeting pokeweed antiviral protein to CD4+ T cells by conjugating it to monoclonal antibodies reactive with CD5, CD7 or CD4 expressed on CD4+ cells, increased its anti-HIV potency up to 1,000-fold. HIV-1 replication is inhibited at picomolar concentrations of conjugates of pokeweed antiviral protein and monoclonal antibodies, which do not inhibit proliferation of normal CD4+ T cells or CD4-dependent responses. These conjugates inhibit HIV-1 protein synthesis and also strongly inhibit HIV-1 production in activated CD4+ T cells from infected patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0028-0836
1476-4687
DOI:10.1038/347092a0